Kamada (NASDAQ:KMDA - Get Free Report) was upgraded by StockNews.com from a "buy" rating to a "strong-buy" rating in a research report issued on Thursday.
Separately, HC Wainwright restated a "buy" rating and issued a $11.00 price objective on shares of Kamada in a research report on Thursday, March 6th.
Check Out Our Latest Analysis on Kamada
Kamada Price Performance
KMDA traded down $0.38 during trading on Thursday, reaching $6.80. 215,546 shares of the company's stock were exchanged, compared to its average volume of 74,764. The company's fifty day simple moving average is $7.24 and its 200-day simple moving average is $6.23. Kamada has a 1 year low of $4.74 and a 1 year high of $9.16. The stock has a market capitalization of $390.86 million, a P/E ratio of 24.29, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.
Institutional Trading of Kamada
Large investors have recently made changes to their positions in the company. Aristides Capital LLC grew its stake in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after acquiring an additional 6,850 shares in the last quarter. Geode Capital Management LLC boosted its stake in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after buying an additional 1,549 shares during the period. NewEdge Advisors LLC increased its holdings in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in shares of Kamada in the 3rd quarter valued at $117,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Kamada during the third quarter worth about $77,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
See Also
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
